IL257840B2 - T cell receptors. The mutant acquaintances of K.R.A.S. limited to human leukocyte antigen - 8 - Google Patents

T cell receptors. The mutant acquaintances of K.R.A.S. limited to human leukocyte antigen - 8

Info

Publication number
IL257840B2
IL257840B2 IL257840A IL25784018A IL257840B2 IL 257840 B2 IL257840 B2 IL 257840B2 IL 257840 A IL257840 A IL 257840A IL 25784018 A IL25784018 A IL 25784018A IL 257840 B2 IL257840 B2 IL 257840B2
Authority
IL
Israel
Prior art keywords
seq
amino acid
acid sequence
val
ile
Prior art date
Application number
IL257840A
Other languages
English (en)
Hebrew (he)
Other versions
IL257840B1 (en
IL257840A (en
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of IL257840A publication Critical patent/IL257840A/en
Publication of IL257840B1 publication Critical patent/IL257840B1/en
Publication of IL257840B2 publication Critical patent/IL257840B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
IL257840A 2015-09-15 2016-09-09 T cell receptors. The mutant acquaintances of K.R.A.S. limited to human leukocyte antigen - 8 IL257840B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562218688P 2015-09-15 2015-09-15
PCT/US2016/050875 WO2017048593A1 (en) 2015-09-15 2016-09-09 T cell receptors recognizing hla-cw8 restricted mutated kras

Publications (3)

Publication Number Publication Date
IL257840A IL257840A (en) 2018-04-30
IL257840B1 IL257840B1 (en) 2023-06-01
IL257840B2 true IL257840B2 (en) 2023-10-01

Family

ID=56985686

Family Applications (1)

Application Number Title Priority Date Filing Date
IL257840A IL257840B2 (en) 2015-09-15 2016-09-09 T cell receptors. The mutant acquaintances of K.R.A.S. limited to human leukocyte antigen - 8

Country Status (13)

Country Link
US (3) US10556940B2 (https=)
EP (2) EP3901169B1 (https=)
JP (2) JP7185524B2 (https=)
KR (2) KR20250117744A (https=)
CN (2) CN115073583A (https=)
AU (3) AU2016323017B2 (https=)
DK (1) DK3350213T3 (https=)
ES (1) ES2879287T3 (https=)
IL (1) IL257840B2 (https=)
MX (1) MX2018003062A (https=)
SA (1) SA518391109B1 (https=)
SG (1) SG10201913868XA (https=)
WO (1) WO2017048593A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2592821B (en) 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
WO2018026691A1 (en) * 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-kras-g12d t cell receptors
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
WO2018183485A1 (en) * 2017-03-31 2018-10-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating neoantigen-specific t cell receptor sequences
US11807662B2 (en) 2017-05-16 2023-11-07 The Johns Hopkins University MANAbodies and methods of using
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
EP3684799A1 (en) 2017-09-20 2020-07-29 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hla class ii restricted t cell receptors against mutated ras
AU2018345400B2 (en) 2017-10-05 2024-06-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for selectively expanding cells expressing a TCR with a murine constant region
EP3720478A1 (en) * 2017-12-04 2020-10-14 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class i-restricted t cell receptors against mutated ras
BR112020025764A2 (pt) * 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
CN112888707B (zh) 2018-08-16 2025-04-25 百欧恩泰美国公司 T细胞受体构建体及其用途
CN113412277B (zh) * 2019-01-22 2025-07-18 美国卫生和人力服务部 针对含有g12r突变的ras的hla第ii类限制性t细胞受体
WO2020172332A1 (en) 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
US20220175899A1 (en) * 2019-04-11 2022-06-09 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer
CN110172089B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
WO2021029046A1 (ja) * 2019-08-14 2021-02-18 日本電気株式会社 情報処理装置、情報処理方法及び記録媒体
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术(广东)有限公司 一种识别Kras G12V的高亲和力TCR
WO2021123832A1 (en) 2019-12-20 2021-06-24 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
AU2021220957A1 (en) * 2020-02-14 2022-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class I-restricted T cell receptors against ras with G12V mutation
CN111574616B (zh) * 2020-06-17 2021-02-02 深圳豪石生物科技有限公司 分离的t细胞受体和应用
CN116348484A (zh) * 2020-07-16 2023-06-27 美国卫生和人力服务部 针对含有g12v突变的ras的hla-ii类限制性drb t细胞受体
TW202540156A (zh) * 2020-10-02 2025-10-16 美國衛生與公眾服務部 針對含有g13d突變之ras之hla第ii類限制性dq t細胞受體
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
CN114920824B (zh) * 2022-05-27 2023-12-05 重庆医科大学 Tcr或其抗原结合片段及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301017B2 (en) * 2002-05-30 2007-11-27 Kolesnick Richard N Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
WO2007017201A1 (en) * 2005-08-05 2007-02-15 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh Generation of antigen specific t cells
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
ES2834070T3 (es) 2011-09-15 2021-06-16 Us Health Receptores de células T que reconocen MAGE restringido por HLA-A1 o HLA-Cw7
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
MX384919B (es) * 2014-11-26 2025-03-14 Us Health Receptores de células t de kras anti-mutado.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FREDERICK D. TSAI ET AL,, K-RAS4A SPLICE VARIANT IS WIDELY EXPRESSED IN CANCER AND USES A HYBRID MEMBRANE-TARGETING MOTIF, 5 January 2015 (2015-01-05) *

Also Published As

Publication number Publication date
AU2021200833B2 (en) 2022-04-28
US10556940B2 (en) 2020-02-11
AU2016323017B2 (en) 2020-11-12
ES2879287T3 (es) 2021-11-22
CN108350059B (zh) 2021-10-08
AU2021200833A1 (en) 2021-03-04
JP7461445B2 (ja) 2024-04-03
JP7185524B2 (ja) 2022-12-07
AU2022209229A1 (en) 2022-09-15
EP3901169B1 (en) 2026-01-28
EP3350213B1 (en) 2021-03-31
SA518391109B1 (ar) 2022-02-14
KR20180044428A (ko) 2018-05-02
US20190040111A1 (en) 2019-02-07
CA2998869A1 (en) 2017-03-23
SG10201913868XA (en) 2020-03-30
WO2017048593A1 (en) 2017-03-23
AU2022209229B2 (en) 2024-05-23
CN115073583A (zh) 2022-09-20
CN108350059A (zh) 2018-07-31
AU2016323017A1 (en) 2018-04-05
DK3350213T3 (da) 2021-06-21
US20230406904A1 (en) 2023-12-21
IL257840B1 (en) 2023-06-01
HK1257902A1 (en) 2019-11-01
JP2018535647A (ja) 2018-12-06
EP3901169A1 (en) 2021-10-27
KR20250117744A (ko) 2025-08-05
EP3350213A1 (en) 2018-07-25
MX2018003062A (es) 2018-09-11
US11667692B2 (en) 2023-06-06
IL257840A (en) 2018-04-30
JP2023025108A (ja) 2023-02-21
US20200148739A1 (en) 2020-05-14
KR102841067B1 (ko) 2025-08-01

Similar Documents

Publication Publication Date Title
US20230406904A1 (en) T cell receptors recognizing hla-cw8 restricted mutated kras
US11840561B2 (en) Anti-KRAS-G12D T cell receptors
US11352410B2 (en) Anti-KK-LC-1 T cell receptors
JP7635165B2 (ja) p53におけるR175H又はY220C変異を認識するT細胞受容体
CA2998869C (en) T cell receptors recognizing hla-cw8 restricted mutated kras
HK1257902B (en) T cell receptors recognizing hla-cw8 restricted mutated kras
CA3032870C (en) Anti-kras-g12d t cell receptors
EP4326751A1 (en) Hla class i-restricted t cell receptors against ras with q61k mutation